Fennec Pharmaceuticals Inc.

Equities

FENC

CA31447P1009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.21 ^USD	+0.55%		-1.39%	-17.91%

Apr. 23	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	MT
Apr. 19	Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	MT

Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

February 29, 2024 at 04:05 pm EST

Fennec Pharmaceuticals Inc. provided unaudited earnings guidance for the fourth quarter and full year of 2023. Fourth quarter 2023 net revenues are expected to be approximately $9.2 million to $9.7 million, which represents approximately a 41%-49% increase over the third quarter of 2023.

Full-year 2023 net revenues are expected to be approximately $20.7 million to $21.2 million.

Latest news about Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	Apr. 23	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	Apr. 19	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	Apr. 17	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	Apr. 05	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	Apr. 04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	Apr. 03	MT
Wedbush on Fennec's Q4	Mar. 21	MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024	Mar. 21
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	Mar. 21	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	Mar. 21	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	Mar. 21	MT
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	Mar. 21	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Wedbush on Fennec's Deal for Pedmarqsi in EU	Mar. 18	MT
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 18	MT
Sector Update: Health Care	Mar. 18	MT
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	Mar. 18	MT
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	Mar. 18	MT
Fennec Pharmaceuticals Signs Exclusive Licensing Deal With Norgine	Mar. 18	MT
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	Mar. 17	CI
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	Feb. 29	CI
Wedbush on Fennec Pharmaceuticals' Pedmark	Feb. 29	MT
Fennec Pharmaceuticals Brief: Full-year 2023 net revenues are expected to be approximately US$20.7 to $21.2 million	Feb. 29	MT

Chart Fennec Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fennec Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.21 USD

Average target price

18.33 USD

Spread / Average Target

+99.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FENNEC PHARMACEUTICALS INC.	-17.91%	250M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs